C E Simmons1, S Hogeveen2, R Leonard1, Y Rajmohan1, D Han2, A Wong2, J Lee3, M Brackstone4, J F Boileau5, R Dinniwell2, S Gandhi6. 1. Division of Medical Oncology, BC Cancer Agency, Vancouver, BC. 2. Division of Medical Oncology, St. Michael's Hospital, Toronto, ON. 3. Division of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON. 4. Division of Surgical Oncology, London Health Sciences Centre, London, ON. 5. Division of Surgical Oncology, Jewish General Hospital, Montreal, QC. 6. Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.
Abstract
BACKGROUND: Use of the neoadjuvant approach to treat breast cancer patients has increased since the early 2000s, but the overall pathway of care for such patients can be highly variable. The aim of our project was to establish a multidisciplinary consensus among clinicians with expertise in neoadjuvant therapy (nat) for breast cancer and to determine if that consensus reflects published methods used in randomized controlled trials (rcts) in this area. METHODS: A modified Delphi protocol, which used iterative surveys administered to 85 experts across Canada, was established to obtain expert consensus concerning all aspects of the care pathway for patients undergoing nat for breast cancer. All rcts published between January 1, 1967, and December 1, 2012, were systematically reviewed. Data extracted from the rcts were analyzed to determine if the methods used matched the expert consensus for specific areas of nat management. A scoring system determined the strength of the agreement between the literature and the expert consensus. RESULTS: Consensus was achieved for all areas of the pathway of care for patients undergoing nat for breast cancer, with the exception of the role of magnetic resonance imaging in the pre-treatment or preoperative setting. The levels of agreement between the consensus statements and the published rcts varied, primarily because specific aspects of the pathway of care were not well described in the reviewed literature. CONCLUSIONS: A true consensus of expert opinion concerning the pathway of care appropriate for patients receiving nat for breast cancer has been achieved. A review of the literature illuminated gaps in the evidence about some elements of nat management. Where evidence is available, agreement with expert opinion is strong overall. Our study is unique in its approach to establishing consensus among medical experts in this field and has established a pathway of care that can be applied in practice for patients receiving nat.
BACKGROUND: Use of the neoadjuvant approach to treat breast cancerpatients has increased since the early 2000s, but the overall pathway of care for such patients can be highly variable. The aim of our project was to establish a multidisciplinary consensus among clinicians with expertise in neoadjuvant therapy (nat) for breast cancer and to determine if that consensus reflects published methods used in randomized controlled trials (rcts) in this area. METHODS: A modified Delphi protocol, which used iterative surveys administered to 85 experts across Canada, was established to obtain expert consensus concerning all aspects of the care pathway for patients undergoing nat for breast cancer. All rcts published between January 1, 1967, and December 1, 2012, were systematically reviewed. Data extracted from the rcts were analyzed to determine if the methods used matched the expert consensus for specific areas of nat management. A scoring system determined the strength of the agreement between the literature and the expert consensus. RESULTS: Consensus was achieved for all areas of the pathway of care for patients undergoing nat for breast cancer, with the exception of the role of magnetic resonance imaging in the pre-treatment or preoperative setting. The levels of agreement between the consensus statements and the published rcts varied, primarily because specific aspects of the pathway of care were not well described in the reviewed literature. CONCLUSIONS: A true consensus of expert opinion concerning the pathway of care appropriate for patients receiving nat for breast cancer has been achieved. A review of the literature illuminated gaps in the evidence about some elements of nat management. Where evidence is available, agreement with expert opinion is strong overall. Our study is unique in its approach to establishing consensus among medical experts in this field and has established a pathway of care that can be applied in practice for patients receiving nat.
Entities:
Keywords:
Breast cancer; consensus; locally advanced breast cancer; neoadjuvant chemotherapy; neoadjuvant endocrine therapy; pathway of care
Authors: Georgiana K Ellis; William E Barlow; Julie R Gralow; Gabriel N Hortobagyi; Christy A Russell; Melanie E Royce; Edith A Perez; Danika Lew; Robert B Livingston Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544
Authors: Banu K Arun; Kapil Dhinghra; Vicente Valero; Shu-Wan Kau; Kristine Broglio; Daniel Booser; Laura Guerra; Guosheng Yin; Ronald Walters; Aysegul Sahin; Nuhad Ibrahim; Aman U Buzdar; Debbie Frye; Nour Sneige; Eric Strom; Merrick Ross; Richard L Theriault; Saroj Vadhan-Raj; Gabriel N Hortobagyi Journal: Oncologist Date: 2011-10-31
Authors: Serban Dan Costa; Sibylle Loibl; Manfred Kaufmann; Dirk-Michael Zahm; Jörn Hilfrich; Jens Huober; Holger Eidtmann; Andreas du Bois; Jens-Uwe Blohmer; Beyhan Ataseven; Erich Weiss; Hans Tesch; Bernd Gerber; Klaus H Baumann; Christoph Thomssen; Georg Peter Breitbach; Shaip Ibishi; Christian Jackisch; Keyur Mehta; Gunter von Minckwitz Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Eva Thomas; Frankie A Holmes; Terry L Smith; Aman U Buzdar; Debra K Frye; Giuseppe Fraschini; S Eva Singletary; Richard L Theriault; Marsha D McNeese; Frederick Ames; Ronald Walters; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: J Dose-Schwarz; R Tiling; S Avril-Sassen; S Mahner; A Lebeau; C Weber; M Schwaiger; F Jänicke; M Untch; N Avril Journal: Br J Cancer Date: 2009-11-17 Impact factor: 7.640
Authors: Ramon Colomer; Cristina Saura; Pedro Sánchez-Rovira; Tomás Pascual; Isabel T Rubio; Octavio Burgués; Lourdes Marcos; César A Rodríguez; Miguel Martín; Ana Lluch Journal: Oncologist Date: 2019-02-01